Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XT-150 in Facet Joint Osteoarthritis Pain
NCT04841512Phase 2Withdrawn
- Sponsor
- Xalud Therapeutics
- Start
- Oct 2021
- Primary completion
- Mar 2022
- Modality
- Gene Editing, Gene Silencing, Plasmid DNA
- Countries
- 1
01
Overview
A Phase 2 trial of XT-150 in facet joint osteoarthritis, sponsored by Xalud Therapeutics. Planned start Oct 2021; status: withdrawn.
02
Drugs
XT-150
03
Conditions
facet joint osteoarthritis
Beyond the preview
Go deeper on NCT04841512.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04841512.